Physical inactivity has consistently been shown to be one of the most powerful, modifiable risk factors for all causes of death and disease, alongside smoking and obesity.
This interactive body map brings together scientific evidence on the links between lack of physical activity and disease.
Click on the coloured dots on the body, or choose a specific disease from the dropdown menu, or cycle through all diseases via the next and previous buttons.
To use the map, click on any of the coloured dots on the body, or choose a specific disease from the dropdown menu. You can also filter by disease or condition type.
This is the first in our package on the benefits of exercise. Read other articles in the package here.
For a copy of the data and notes on the methodology used for the calculations, please visit The Conversation’s GitHub page.
Carol Maher receives funding from the National Health and Medical Research Council and the National Heart Foundation.
Tim Olds receives funding from the ARC and the NHMRC.
This article was originally published on The Conversation. Read the original article.


Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility?
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds
France Keeps Top Health Alert as Officials Brace for Another Heatwave
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 



